

# Kunihiko Kobayashi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9249743/publications.pdf>

Version: 2024-02-01

31  
papers

1,404  
citations

623188

14  
h-index

433756

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1902  
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 625-635.	5.1	470
2	Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 115-123.	0.8	327
3	Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). <i>Targeted Oncology</i> , 2013, 8, 27-33.	1.7	89
4	Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019, 10, 775-781.	0.8	64
5	CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 819-826.	0.5	61
6	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 725.	1.0	46
7	A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. <i>Lung Cancer</i> , 2016, 99, 131-136.	0.9	44
8	Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. <i>Thoracic Cancer</i> , 2019, 10, 992-1000.	0.8	44
9	Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. <i>Thoracic Cancer</i> , 2020, 11, 1280-1287.	0.8	37
10	Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 873-880.	1.1	32
11	Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 975-979.	0.8	25
12	Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 $\geq$ 50%. <i>Scientific Reports</i> , 2020, 10, 14990.	1.6	23
13	Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 6971-6984.	1.3	21
14	Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7515-7515.	0.8	14
15	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 817-825.	1.1	13
16	Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B. <i>Thoracic Cancer</i> , 2020, 11, 1876-1884.	0.8	13
17	A phase II study of first-line afatinib for patients aged $\geq$ 75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. <i>BMC Cancer</i> , 2021, 21, 208.	1.1	13
18	Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. <i>Journal of Clinical Medicine</i> , 2021, 10, 3744.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. <i>Thoracic Cancer</i> , 2021, 12, 864-873.	0.8	10
20	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. <i>Frontiers in Oncology</i> , 2021, 11, 610952.	1.3	10
21	A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). <i>Lung Cancer</i> , 2014, 86, 195-200.	0.9	8
22	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1479-1489.	0.8	6
23	Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell-like features. <i>Thoracic Cancer</i> , 2020, 11, 3609-3613.	0.8	4
24	A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A 1.1 (trial in progress). <i>BMC Cancer</i> , 2020, 20, 961.		3
25	Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 5309-5311.	0.5	3
26	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. <i>Oncology</i> , 2021, 99, 562-570.	0.9	3
27	Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from <i>Mycobacterium tuberculosis</i> : A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 227.	0.4	3
28	First-line gefitinib for elderly patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: A combined analysis of NEJ studies. <i>Journal of Clinical Oncology</i> , 2012, 30, 7563-7563.	0.8	3
29	A phase II study of erlotinib monotherapy in patients with previously treated advanced non-small cell lung cancer (NSCLC) without EGFR gene mutation who have never/light smoking history: NEJ006/TCOG0903. <i>Journal of Clinical Oncology</i> , 2012, 30, 7561-7561.	0.8	2
30	Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1171-1179.	0.8	1
31	Content Validity and Feasibility of the Care Notebook to Assess Cancer-Related Quality of Life in Hawaii. <i>Annals of Cancer Research and Therapy</i> , 2012, 20, 68-72.	0.1	0